Literature DB >> 6875258

The effect of pre-injection of mice with pristane on ascites tumour formation and monoclonal antibody production.

N Hoogenraad, T Helman, J Hoogenraad.   

Abstract

Experiments were performed to determine whether for mice pre-injected with pristane (2,6,10,14-tetramethylpentadecane) there is an optimum interval before injection of hybridomas in order to maximize ascites fluid formation and yield of monoclonal antibodies. With injections of 0.5 ml of pristane followed by injections of 5 x 10(5) hybridoma cells making monoclonal antibodies against mammalian carbamyl phosphate synthetase, a pre-injection time of 10 days was optimum with respect to (a) the time taken for the ascites tumours to appear; (b) the percentage of mice developing ascites tumours (all mice developed tumours over a span of 2 days); and (c) the concentration of monoclonal antibodies in ascites fluid: 11 mg/ml compared with 7 mg/ml for the next highest group.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875258     DOI: 10.1016/0022-1759(83)90225-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  16 in total

1.  Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen.

Authors:  J L Curtis; P K Byrd; M L Warnock; H B Kaltreider
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

2.  Monoclonal antibody analysis of p53 expression in normal and transformed cells.

Authors:  J W Yewdell; J V Gannon; D P Lane
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus.

Authors:  E Nagy; I Berczi; A H Sehon
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  A 38,000-dalton membrane protein (p38) present in synaptic vesicles.

Authors:  R Jahn; W Schiebler; C Ouimet; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  IL-1α modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil.

Authors:  Pui Y Lee; Yutaro Kumagai; Yuan Xu; Yi Li; Tolga Barker; Chao Liu; Eric S Sobel; Osamu Takeuchi; Shizuo Akira; Minoru Satoh; Westley H Reeves
Journal:  J Immunol       Date:  2010-12-29       Impact factor: 5.422

6.  A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas.

Authors:  K Bosslet; H F Kern; E J Kanzy; A Steinstraesser; A Schwarz; G Lüben; H U Schorlemmer; H H Sedlacek
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Topographical analysis of the G virion of Aleutian mink disease parvovirus with monoclonal antibodies.

Authors:  D L Barnard; F B Johnson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans.

Authors:  C H Mody; G H Chen; C Jackson; J L Curtis; G B Toews
Journal:  Mycopathologia       Date:  1994-01       Impact factor: 2.574

9.  Salmonella serogroups C2 and C3 identified by agglutination using an immunoglobulin G3(kappa) monoclonal antibody (32-1-E3) reactive with a somatic factor 8-like polysaccharide antigen.

Authors:  P S Duffey; J C Kani; J O Lee; W J Hill; R Kokka
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

10.  TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.

Authors:  Pui Y Lee; Yutaro Kumagai; Yi Li; Osamu Takeuchi; Hideo Yoshida; Jason Weinstein; Erinn S Kellner; Dina Nacionales; Tolga Barker; Kindra Kelly-Scumpia; Nico van Rooijen; Himanshu Kumar; Taro Kawai; Minoru Satoh; Shizuo Akira; Westley H Reeves
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.